Given the cardioprotective and renoprotective effects of SGLT2 inhibitors, should we consider administering to patients with well controlled type 1 diabetes despite the risk of DKA?

Topics: Chronic kidney disease • Nephrology • Endocrinology

Answer from: at Community Practice

The key word in this question is "consider". GIven the lack of published clinical trials to assess efficacy (CV and CKD hard outcomes) versus safety (DKA) in this population, an answer at this time would be a qualified yes, with the qualifications being a well-motivated patient who adheres to self-g...

Comments

at Nephrology Associates
Thank you. I agree.

at Uchealth University Of Colorado Hospital
I would not use in T1DM without patient consent. T...

Answer from: at Community Practice

It has been approved for use in Europe for type I DM.

Related Questions